The FDA initiated approval of leucovorin calcium tablets to treat cerebral folate deficiency (CFD) following a systematic analysis demonstrating promise in this patient population.
A large cohort study explored whether semaglutide and tirzepatide influence risks of dementia, stroke, and survival in adults with diabetes and obesity.
Agitation in frontotemporal lobar degeneration is linked to distinct neuropsychiatric symptom profiles between men and women, with men showing a broader spectrum of associated symptoms, particularly in...
New clinical guidance outlines the use of blood-based biomarker tests for Alzheimer’s diagnosis in patients with cognitive impairment, aiming to support more consistent and evidence-based application in...
Results from a phase 2B randomized, double-blind, placebo-controlled trial suggest that semaglutide not only reduces inflammation and adiposity in people with HIV but may also provide a neurocognitive...
A randomized controlled trial reveals that children with ADHD and ASD have distinct gut microbiota signatures, and that probiotic supplementation alters these profiles, offering promising insights for...
A large cohort study of adolescents found that higher restricted normalized isotropic (RNI) values—an MRI-based marker of brain microstructure—were associated with greater weight gain over 2 years,...
In a phase 3 trial, tolebrutinib, an oral Bruton’s tyrosine kinase inhibitor, significantly reduced the risk of sustained disability progression in patients with nonrelapsing secondary progressive multiple...
Patients who experience a transient ischemic attack or minor stroke face a nearly 20% risk of a subsequent stroke within 10 years, according to a large meta-analysis of more than 170,000 individuals.
In a recent multicenter study, brexpiprazole showed significant efficacy in reducing agitation symptoms in Japanese patients with Alzheimer dementia, marking the first confirmation of its effectiveness in...
